Botulinum toxin type E: phase 3 results show effect within 8 hours and a short duration
- The Aesthetic Surgery Journal published phase 3 results for trenibotulinumtoxinE in frown lines.
- At day 7, 60.0% responded to trenibotulinumtoxinE versus 0.6% on placebo.
- With trenibotulinumtoxinE, improvement began at 8 hours, peaked at day 7 and lines returned by day 21.
- Most side effects of trenibotulinumtoxinE were mild, and the product is still investigational.
Familiar Botox-type products use botulinum toxin type A, whereas trenibotulinumtoxinE (trenibotE) uses serotype E. The Aesthetic Surgery Journal published results of its pivotal phase 3 trial for glabellar (frown) lines on 25 October 2026.
Study design
The double-blind, placebo-controlled trial enrolled adults with moderate-to-severe frown lines, including people who had and had not received toxin before. Participants were randomised 3:1 to 700 units of trenibotE or placebo. The success bar was strict: lines rated none or mild with at least a two-grade improvement, judged by both investigator and participant. The trial also tracked participants whose appearance affected them psychologically.
Results
- At day 7, 60.0% responded on trenibotE versus 0.6% on placebo.
- Improvement began at hour 8, peaked at day 7, and lines returned to moderate-to-severe by day 21.
- Treatment satisfaction at day 7 was 77.6% vs 5.1%, and satisfaction with natural-looking results 78.5% vs 9.0%.
- Most adverse events were mild and nonserious.
Why it matters
A fast-acting, short-lasting option may suit people who hesitate to try toxin for the first time because they worry about a long-lasting result. Allergan Aesthetics describes trenibotE as investigational, meaning it is not yet approved.
Sources: Aesthetic Surgery Journal via PubMed, Allergan Aesthetics via PR Newswire
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is trenibotulinumtoxinE?
TrenibotulinumtoxinE (trenibotE) is a botulinum toxin serotype E being developed to treat frown lines between the eyebrows.
What were the phase 3 results for trenibotulinumtoxinE?
At day 7, 60.0% of participants responded to trenibotulinumtoxinE versus 0.6% on placebo.
How fast does trenibotulinumtoxinE work and how long does it last?
TrenibotulinumtoxinE began working at about 8 hours, peaked at day 7, and frown lines returned by day 21.
Was trenibotulinumtoxinE safe in the phase 3 trial?
Most adverse events with trenibotulinumtoxinE in the phase 3 trial were mild, nonserious and unrelated to treatment.
Is trenibotulinumtoxinE available?
No. Allergan Aesthetics describes trenibotulinumtoxinE as an investigational product.



